SCOPUS 정보 검색 플랫폼

Volumn 31, Issue 1, 2010, Pages 22-28

Molecular diagnostics in lung carcinoma for therapy stratification;Molekulardiagnostik des Lungenkarzinoms zur Therapiestratifizierung

(2) Heukamp, L C a Buttner R a

a UNIVERSITY HOSPITAL BONN (Germany)

Author keywords

EGFR; Erlotinib; Gefitinib; Lung cancer; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ARTICLE; CANCER STAGING; DIAGNOSTIC PROCEDURE; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; HUMAN; LUNG; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MORTALITY; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; PROGNOSIS; PROTEIN-TYROSINE KINASES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR MARKERS, BIOLOGICAL;

EID: 77949269480 PISSN: 01728113 EISSN: None Source Type: Journal
DOI: 10.1007/s00292-009-1241-1 Document Type: Article

Times cited : (5)

References (82)

1
- 0035883542
- Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung
- DOI 10.1002/1097-0142(20010915)92:6<1525::AID-CNCR1478>3.0.CO;2-H
- Ahrendt 2001 Cancer 92 1525 10.1002/1097-0142(20010915)92:6<1525::AID- CNCR1478>3.0.CO;2-H 11745231 1:CAS:528:DC%2BD3MXnvVygsr0%3D (Pubitemid 32947838)
- (2001) Cancer , vol.92 , Issue.6 , pp. 1525-1530
- Ahrendt, S.A.¹ Anthony Decker, P.² Alawi, E.A.³ Zhu, Y.-R.⁴ Sanchez-Cespedes, M.⁵ Yang, S.C.⁶ Haasler, G.B.⁷ Kajdacsy-Balla, A.⁸ Demeure, M.J.⁹ Sidransky, D.¹⁰

2
- 0032719534
- 10537357 1:CAS:528:DyaK1MXntlGlur0%3D
- Akimoto 1999 Clin Cancer Res 5 2884 10537357 1:CAS:528:DyaK1MXntlGlur0%3D
- (1999) Clin Cancer Res , vol.5 , pp. 2884
- Akimoto¹

3
- 33645506849
- 10.1158/0008-5472.CAN-05-3757 16540667 1:CAS:528:DC%2BD28Xitlertrc%3D
- Alvarez 2006 Cancer Res 66 3162 10.1158/0008-5472.CAN-05-3757 16540667 1:CAS:528:DC%2BD28Xitlertrc%3D
- (2006) Cancer Res , vol.66 , pp. 3162
- Alvarez¹

4
- 33751292685
- Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors
- DOI 10.1158/1078-0432.CCR-06-1570
- Balak 2006 Clin Cancer Res 12 6494 10.1158/1078-0432.CCR-06-1570 17085664 1:CAS:528:DC%2BD28XhtFKitbrI (Pubitemid 44799723)
- (2006) Clinical Cancer Research , vol.12 , Issue.21 , pp. 6494-6501
- Balak, M.N.¹ Gong, Y.² Riely, G.J.³ Somwar, R.⁴ Li, A.R.⁵ Zakowski, M.F.⁶ Chiang, A.⁷ Yang, G.⁸ Ouerfelli, O.⁹ Kris, M.G.¹⁰ Ladanyi, M.¹¹ Miller, V.A.¹² Pao, W.¹³

5
- 0028040812
- 7518560 1:CAS:528:DyaK2cXlt1Gnur8%3D
- Batzer 1994 Mol Cell Biol 14 5192 7518560 1:CAS:528:DyaK2cXlt1Gnur8%3D
- (1994) Mol Cell Biol , vol.14 , pp. 5192
- Batzer¹

6
- 34047248571
- Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies
- DOI 10.1158/0008-5472.CAN-06-4158
- Benvenuti 2007 Cancer Res 67 2643 10.1158/0008-5472.CAN-06-4158 17363584 1:CAS:528:DC%2BD2sXivV2ns7w%3D (Pubitemid 46548951)
- (2007) Cancer Research , vol.67 , Issue.6 , pp. 2643-2648
- Benvenuti, S.¹ Sartore-Bianchi, A.² Di Nicolantonio, F.³ Zanon, C.⁴ Moroni, M.⁵ Veronese, S.⁶ Siena, S.⁷ Bardelli, A.⁸

7
- 33748445361
- Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada clinical trials group study BR.21
- DOI 10.1200/JCO.2006.05.8073
- Bezjak 2006 J Clin Oncol 24 3831 10.1200/JCO.2006.05.8073 16921034 1:CAS:528:DC%2BD28Xps1Sitr8%3D (Pubitemid 46630729)
- (2006) Journal of Clinical Oncology , vol.24 , Issue.24 , pp. 3831-3837
- Bezjak, A.¹ Tu, D.² Seymour, L.³ Clark, G.⁴ Trajkovic, A.⁵ Zukin, M.⁶ Ayoub, J.⁷ Lago, S.⁸ Ribeiro, R.D.A.⁹ Gerogianni, A.¹⁰ Cyjon, A.¹¹ Noble, J.¹² Laberge, F.¹³ Chan, R.T.-T.¹⁴ Fenton, D.¹⁵ Von Pawel, J.¹⁶ Reck, M.¹⁷ Shepherd, F.A.¹⁸

8
- 33646888233
- Where next for gefitinib in patients with lung cancer?
- DOI 10.1016/S1470-2045(06)70725-2, PII S1470204506707252
- Blackhall 2006 Lancet Oncol 7 499 10.1016/S1470-2045(06)70725-2 16750500 1:CAS:528:DC%2BD28XltFClsLg%3D (Pubitemid 43779172)
- (2006) Lancet Oncology , vol.7 , Issue.6 , pp. 499-507
- Blackhall, F.¹ Ranson, M.² Thatcher, N.³

9
- 33745683527
- Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy
- DOI 10.1158/1078-0432.CCR-06-0261
- Bunn 2006 Clin Cancer Res 12 3652 10.1158/1078-0432.CCR-06-0261 16778092 1:CAS:528:DC%2BD28XlvVSls7k%3D (Pubitemid 44000246)
- (2006) Clinical Cancer Research , vol.12 , Issue.12 , pp. 3652-3656
- Bunn Jr., P.A.¹ Dziadziuszko, R.² Varella-Garcia, M.³ Franklin, W.A.⁴ Witta, S.E.⁵ Kelly, K.⁶ Hirsch, F.R.⁷

10
- 0033543544
- The role of individual SH2 domains in mediating association of phospholipase C-γ1 with the activated EGF receptor
- DOI 10.1074/jbc.274.37.26091
- Chattopadhyay 1999 J Biol Chem 274 26091 10.1074/jbc.274.37.26091 10473558 1:CAS:528:DyaK1MXmtVKmtLw%3D (Pubitemid 29437052)
- (1999) Journal of Biological Chemistry , vol.274 , Issue.37 , pp. 26091-26097
- Chattopadhyay, A.¹ Vecchi, M.² Ji, Q.-S.³ Mernaugh, R.⁴ Carpenter, G.⁵

11
- 0034093597
- 10810374 1:CAS:528:DC%2BD3cXjsVertLw%3D
- Chen 2000 Anticancer Res 20 899 10810374 1:CAS:528:DC%2BD3cXjsVertLw%3D
- (2000) Anticancer Res , vol.20 , pp. 899
- Chen¹

12
- 0034799139
- 11595683 1:CAS:528:DC%2BD3MXnvF2ktbk%3D
- Ciardiello 2001 Clin Cancer Res 7 2958 11595683 1:CAS:528: DC%2BD3MXnvF2ktbk%3D
- (2001) Clin Cancer Res , vol.7 , pp. 2958
- Ciardiello¹

13
- 0038501053
- Targeting epidermal growth factor receptor - Are we missing the mark?
- DOI 10.1016/S0140-6736(03)13810-X
- Dancey 2003 Lancet 362 62 10.1016/S0140-6736(03)13810-X 12853203 1:CAS:528:DC%2BD3sXltF2is7w%3D (Pubitemid 36835824)
- (2003) Lancet , vol.362 , Issue.9377 , pp. 62-64
- Dancey, J.E.¹ Freidlin, B.²

14
- 40149088765
- De 2008 Ann Oncol 19 508
- (2008) Ann Oncol , vol.19 , pp. 508
- De¹

15
- 57449095367
- 10.1200/JCO.2008.18.0786 1:CAS:528:DC%2BD1MXotFemsA%3D%3D
- Di 2008 J Clin Oncol 26 5705 10.1200/JCO.2008.18.0786 1:CAS:528:DC%2BD1MXotFemsA%3D%3D
- (2008) J Clin Oncol , vol.26 , pp. 5705
- Di¹

16
- 77949261829
- Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: A randomized, open-label phase III study (INTEREST)
- Seoul, South Korea
- Douillard J-YKE, Hirsh V (2007) Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase III study (INTEREST). In: 12th World Conference on Lung Cancer. Seoul, South Korea
- (2007) 12th World Conference on Lung Cancer
- J-Yke, D.¹ Hirsh, V.²

17
- 24944497744
- Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
- DOI 10.1200/JCO.2005.02.857
- Eberhard 2005 J Clin Oncol 23 5900 10.1200/JCO.2005.02.857 16043828 1:CAS:528:DC%2BD2MXhtVKgtbzO (Pubitemid 46300206)
- (2005) Journal of Clinical Oncology , vol.23 , Issue.25 , pp. 5900-5909
- Eberhard, D.A.¹ Johnson, B.E.² Amler, L.C.³ Goddard, A.D.⁴ Heldens, S.L.⁵ Herbst, R.S.⁶ Ince, W.L.⁷ Janne, P.A.⁸ Januario, T.⁹ Johnson, D.H.¹⁰ Klein, P.¹¹ Miller, V.A.¹² Ostland, M.A.¹³ Ramies, D.A.¹⁴ Sebisanovic, D.¹⁵ Stinson, J.A.¹⁶ Zhang, Yu.R.¹⁷ Seshagiri, S.¹⁸ Hillan, K.J.¹⁹

18
- 34249075147
- MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
- DOI 10.1126/science.1141478
- Engelman 2007 Science 316 1039 10.1126/science.1141478 17463250 1:CAS:528:DC%2BD2sXltlOjt7g%3D (Pubitemid 46799492)
- (2007) Science , vol.316 , Issue.5827 , pp. 1039-1043
- Engelman, J.A.¹ Zejnullahu, K.² Mitsudomi, T.³ Song, Y.⁴ Hyland, C.⁵ Joon, O.P.⁶ Lindeman, N.⁷ Gale, C.-M.⁸ Zhao, X.⁹ Christensen, J.¹⁰ Kosaka, T.¹¹ Holmes, A.J.¹² Rogers, A.M.¹³ Cappuzzo, F.¹⁴ Mok, T.¹⁵ Lee, C.¹⁶ Johnson, B.E.¹⁷ Cantley, L.C.¹⁸ Janne, P.A.¹⁹

19
- 0012381722
- Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
- DOI 10.1200/JCO.2003.10.038
- Fukuoka 2003 J Clin Oncol 21 2237 10.1200/JCO.2003.10.038 12748244 1:CAS:528:DC%2BD2cXpsVGqu7w%3D (Pubitemid 46621858)
- (2003) Journal of Clinical Oncology , vol.21 , Issue.12 , pp. 2237-2246
- Fukuoka, M.¹ Yano, S.² Giaccone, G.³ Tamura, T.⁴ Nakagawa, K.⁵ Douillard, J.-Y.⁶ Nishiwaki, Y.⁷ Vansteenkiste, J.⁸ Kudoh, S.⁹ Rischin, D.¹⁰ Eek, R.¹¹ Horai, T.¹² Noda, K.¹³ Takata, I.¹⁴ Smit, E.¹⁵ Averbuch, S.¹⁶ Macleod, A.¹⁷ Feyereislova, A.¹⁸ Dong, R.-P.¹⁹ Baselga, J.²⁰ more..

20
- 34249723218
- Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
- DOI 10.1038/sj.onc.1210381, PII 1210381
- Galizia 2007 Oncogene 26 3654 10.1038/sj.onc.1210381 17530019 1:CAS:528:DC%2BD2sXlslCqtr4%3D (Pubitemid 46842715)
- (2007) Oncogene , vol.26 , Issue.25 , pp. 3654-3660
- Galizia, G.¹ Lieto, E.² De Vita, F.³ Orditura, M.⁴ Castellano, P.⁵ Troiani, T.⁶ Imperatore, V.⁷ Ciardiello, F.⁸

21
- 84887212361
- 10.1371/journal.pone.0004576 19238210 1:CAS:528:DC%2BD1MXislOqsbw%3D
- Gandhi 2009 PLoS ONE 4 e4576 10.1371/journal.pone.0004576 19238210 1:CAS:528:DC%2BD1MXislOqsbw%3D
- (2009) PLoS ONE , vol.4 , pp. 4576
- Gandhi¹

22
- 34248140107
- Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva lung cancer investigation trial
- DOI 10.1200/JCO.2005.05.1474
- Gatzemeier 2007 J Clin Oncol 25 1545 10.1200/JCO.2005.05.1474 17442998 1:CAS:528:DC%2BD2sXlsVynur4%3D (Pubitemid 46733081)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.12 , pp. 1545-1552
- Gatzemeier, U.¹ Pluzanska, A.² Szczesna, A.³ Kaukel, E.⁴ Roubec, J.⁵ De Rosa, F.⁶ Milanowski, J.⁷ Karnicka-Mlodkowski, H.⁸ Pesek, M.⁹ Serwatowski, P.¹⁰ Ramlau, R.¹¹ Janaskova, T.¹² Vansteenkiste, J.¹³ Strausz, J.¹⁴ Manikhas, G.M.¹⁵ Von Pawel, J.¹⁶

23
- 0032940738
- Endocrine response and resistance in breast cancer: A role for the transcription factor fos
- DOI 10.1002/(SICI)1097-0215(19990219)84:1<54::AID-IJC11>3.0.CO;2-X
- Gee 1999 Int J Cancer 84 54 10.1002/(SICI)1097-0215(19990219)84:1<54:: AID-IJC11>3.0.CO;2-X 9988233 1:STN:280:DyaK1M7ktVOgsA%3D%3D (Pubitemid 29059109)
- (1999) International Journal of Cancer , vol.84 , Issue.1 , pp. 54-61
- Gee, J.M.W.¹ Willsher, P.C.² Kenny, F.S.³ Robertson, J.F.R.⁴ Pinder, S.E.⁵ Ellis, I.O.⁶ Nicholson, R.I.⁷

24
- 1542503746
- Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1
- DOI 10.1200/JCO.2004.08.001
- Giaccone 2004 J Clin Oncol 22 777 10.1200/JCO.2004.08.001 14990632 1:CAS:528:DC%2BD2cXpsVKjur4%3D (Pubitemid 41103588)
- (2004) Journal of Clinical Oncology , vol.22 , Issue.5 , pp. 777-784
- Giaccone, G.¹ Herbst, R.S.² Manegold, C.³ Scagliotti, G.⁴ Rosell, R.⁵ Miller, V.⁶ Natale, R.B.⁷ Schiller, J.H.⁸ Von Pawel, J.⁹ Pluzanska, A.¹⁰ Gatzemeier, U.¹¹ Grous, J.¹² Ochs, J.S.¹³ Averbuch, S.D.¹⁴ Wolf, M.K.¹⁵ Rennie, P.¹⁶ Fandi, A.¹⁷ Johnson, D.H.¹⁸

25
- 0038718522
- 12813169
- Grunwald 2003 J Natl Cancer Inst 95 851 12813169
- (2003) J Natl Cancer Inst , vol.95 , pp. 851
- Grunwald¹

26
- 33646418681
- 10.1158/1078-0432.CCR-05-2845 16638863 1:CAS:528:DC%2BD28XjvValu7o%3D
- Han 2006 Clin Cancer Res 12 2538 10.1158/1078-0432.CCR-05-2845 16638863 1:CAS:528:DC%2BD28XjvValu7o%3D
- (2006) Clin Cancer Res , vol.12 , pp. 2538
- Han¹

27
- 1542713370
- Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2
- DOI 10.1200/JCO.2004.07.215
- Herbst 2004 J Clin Oncol 22 785 10.1200/JCO.2004.07.215 14990633 1:CAS:528:DC%2BD2cXpsVKjur0%3D (Pubitemid 41103589)
- (2004) Journal of Clinical Oncology , vol.22 , Issue.5 , pp. 785-794
- Herbst, R.S.¹ Giaccone, G.² Schiller, J.H.³ Natale, R.B.⁴ Miller, V.⁵ Manegold, C.⁶ Scagliotti, G.⁷ Rosell, R.⁸ Oliff, I.⁹ Reeves, J.A.¹⁰ Wolf, M.K.¹¹ Krebs, A.D.¹² Averbuch, S.D.¹³ Ochs, J.S.¹⁴ Grous, J.¹⁵ Fandi, A.¹⁶ Johnson, D.H.¹⁷

28
- 24944440830
- TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
- DOI 10.1200/JCO.2005.02.840
- Herbst 2005 J Clin Oncol 23 5892 10.1200/JCO.2005.02.840 16043829 1:CAS:528:DC%2BD2MXhtVKgtbzN (Pubitemid 46300205)
- (2005) Journal of Clinical Oncology , vol.23 , Issue.25 , pp. 5892-5899
- Herbst, R.S.¹ Prager, D.² Hermann, R.³ Fehrenbacher, L.⁴ Johnson, B.E.⁵ Sandler, A.⁶ Kris, M.G.⁷ Tran, H.T.⁸ Klein, P.⁹ Li, X.¹⁰ Ramies, D.¹¹ Johnson, D.H.¹² Miller, V.A.¹³

29
- 70349342712
- 10.1200/JCO.2009.23.6661 19667260 1:CAS:528:DC%2BD1MXht1WisbvE
- Horn 2009 J Clin Oncol 27 4232 10.1200/JCO.2009.23.6661 19667260 1:CAS:528:DC%2BD1MXht1WisbvE
- (2009) J Clin Oncol , vol.27 , pp. 4232
- Horn¹

30
- 0023948602
- 3258189 1:CAS:528:DyaL1cXitVamsLk%3D
- Humphrey 1988 Cancer Res 48 2231 3258189 1:CAS:528:DyaL1cXitVamsLk%3D
- (1988) Cancer Res , vol.48 , pp. 2231
- Humphrey¹

31
- 18344390418
- ERBB receptors and cancer: The complexity of targeted inhibitors
- DOI 10.1038/nrc1609
- Hynes 2005 Nature Rev 5 341 10.1038/nrc1609 1:CAS:528: DC%2BD2MXjslertb0%3D (Pubitemid 40637826)
- (2005) Nature Reviews Cancer , vol.5 , Issue.5 , pp. 341-354
- Hynes, N.E.¹ Lane, H.A.²

32
- 33846457870
- 10.3322/canjclin.57.1.43 17237035
- Jemal 2007 CA Cancer J Clin 57 43 10.3322/canjclin.57.1.43 17237035
- (2007) CA Cancer J Clin , vol.57 , pp. 43
- Jemal¹

33
- 0028333768
- 10.1016/0955-0674(94)90141-4 8024815 1:CAS:528:DyaK2cXmsFWku7c%3D
- Johnson 1994 Curr Opin Cell Biol 6 230 10.1016/0955-0674(94)90141-4 8024815 1:CAS:528:DyaK2cXmsFWku7c%3D
- (1994) Curr Opin Cell Biol , vol.6 , pp. 230
- Johnson¹

34
- 0037429737
- Epidermal growth factor receptor: Mechanisms of activation and signalling
- DOI 10.1016/S0014-4827(02)00098-8
- Jorissen 2003 Exp Cell Res 284 31 10.1016/S0014-4827(02)00098-8 12648464 1:CAS:528:DC%2BD3sXitVyltr0%3D (Pubitemid 36331965)
- (2003) Experimental Cell Research , vol.284 , Issue.1 , pp. 31-53
- Jorissen, R.N.¹ Walker, F.² Pouliot, N.³ Garrett, T.P.J.⁴ Ward, C.W.⁵ Burgess, A.W.⁶

35
- 70349863393
- 10.1126/science.326-218 19815749 1:CAS:528:DC%2BD1MXhsFarurvE
- Kaiser 2009 Science 326 218 10.1126/science.326-218 19815749 1:CAS:528:DC%2BD1MXhsFarurvE
- (2009) Science , vol.326 , pp. 218
- Kaiser¹

36
- 34548238762
- Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab
- DOI 10.1200/JCO.2006.10.5437
- Khambata-Ford 2007 J Clin Oncol 25 3230 10.1200/JCO.2006.10.5437 17664471 1:CAS:528:DC%2BD2sXhtVWqs7rF (Pubitemid 47325606)
- (2007) Journal of Clinical Oncology , vol.25 , Issue.22 , pp. 3230-3237
- Khambata-Ford, S.¹ Garrett, C.R.² Meropol, N.J.³ Basik, M.⁴ Harbison, C.T.⁵ Wu, S.⁶ Wong, T.W.⁷ Huang, X.⁸ Takimoto, C.H.⁹ Godwin, A.K.¹⁰ Tan, B.R.¹¹ Krishnamurthi, S.S.¹² Burris III, H.A.¹³ Poplin, E.A.¹⁴ Hidalgo, M.¹⁵ Baselga, J.¹⁶ Clark, E.A.¹⁷ Mauro, D.J.¹⁸

37
- 13844317894
- EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
- DOI 10.1056/NEJMoa044238
- Kobayashi 2005 N Engl J Med 352 786 10.1056/NEJMoa044238 15728811 1:CAS:528:DC%2BD2MXhsFCiurk%3D (Pubitemid 40271173)
- (2005) New England Journal of Medicine , vol.352 , Issue.8 , pp. 786-792
- Kobayashi, S.¹ Boggon, T.J.² Dayaram, T.³ Janne, P.A.⁴ Kocher, O.⁵ Meyerson, M.⁶ Johnson, B.E.⁷ Eck, M.J.⁸ Tenen, D.G.⁹ Halmos, B.¹⁰

38
- 0142055937
- Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients with Non-Small Cell Lung Cancer: A Randomized Trial
- DOI 10.1001/jama.290.16.2149
- Kris 2003 JAMA 290 2149 10.1001/jama.290.16.2149 14570950 1:CAS:528:DC%2BD3sXosVOnsbo%3D (Pubitemid 37432975)
- (2003) Journal of the American Medical Association , vol.290 , Issue.16 , pp. 2149-2158
- Kris, M.G.¹ Natale, R.B.² Herbst, R.S.³ Lynch Jr., T.J.⁴ Prager, D.⁵ Belani, C.P.⁶ Schiller, J.H.⁷ Kelly, K.⁸ Spiridonidis, H.⁹ Sandler, A.¹⁰ Albain, K.S.¹¹ Cella, D.¹² Wolf, M.K.¹³ Averbuch, S.D.¹⁴ Ochs, J.J.¹⁵ Kay, A.C.¹⁶

39
- 43249096031
- 10.1200/JCO.2007.12.1178 18375904 1:CAS:528:DC%2BD1cXltlWhs7w%3D
- Kumar 2008 J Clin Oncol 26 1742 10.1200/JCO.2007.12.1178 18375904 1:CAS:528:DC%2BD1cXltlWhs7w%3D
- (2008) J Clin Oncol , vol.26 , pp. 1742
- Kumar¹

40
- 0026517759
- 10.1016/0167-4889(92)90042-A 1554751 1:CAS:528:DyaK38XhvVyiur4%3D
- Kwatra 1992 Biochim Biophys Acta 1134 178 10.1016/0167-4889(92)90042-A 1554751 1:CAS:528:DyaK38XhvVyiur4%3D
- (1992) Biochim Biophys Acta , vol.1134 , pp. 178
- Kwatra¹

41
- 33749018219
- Mechanisms of cutaneous toxicities to EGFR inhibitors
- DOI 10.1038/nrc1970, PII NRC1970
- Lacouture 2006 Nat Rev Cancer 6 803 10.1038/nrc1970 16990857 1:CAS:528:DC%2BD28XpvVClsr4%3D (Pubitemid 44450468)
- (2006) Nature Reviews Cancer , vol.6 , Issue.10 , pp. 803-812
- Lacouture, M.E.¹

42
- 43749090705
- Clinical testing experience and relationship to EGFR gene copy number and immunohistochemical expression
- DOI 10.2353/jmoldx.2008.070178
- Li 2008 J Mol Diagn 10 242 10.2353/jmoldx.2008.070178 18403609 1:CAS:528:DC%2BD1cXmt1aitrw%3D (Pubitemid 351692167)
- (2008) Journal of Molecular Diagnostics , vol.10 , Issue.3 , pp. 242-248
- Li, A.R.¹ Chitale, D.² Riely, G.J.³ Pao, W.⁴ Miller, V.A.⁵ Zakowski, M.F.⁶ Rusch, V.⁷ Kris, M.G.⁸ Ladanyi, M.⁹

43
- 17444403242
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximab
- DOI 10.1016/j.ccr.2005.03.003
- Li 2005 Cancer Cell 7 301 10.1016/j.ccr.2005.03.003 15837620 1:CAS:528:DC%2BD2MXjvFSkurk%3D (Pubitemid 40544648)
- (2005) Cancer Cell , vol.7 , Issue.4 , pp. 301-311
- Li, S.¹ Schmitz, K.R.² Jeffrey, P.D.³ Wiltzius, J.J.W.⁴ Kussie, P.⁵ Ferguson, K.M.⁶

44
- 33646228635
- 10.1158/0008-5472.CAN-06-0191 16618717 1:CAS:528:DC%2BD28XjsFSlsb0%3D
- Lievre 2006 Cancer Res 66 3992 10.1158/0008-5472.CAN-06-0191 16618717 1:CAS:528:DC%2BD28XjsFSlsb0%3D
- (2006) Cancer Res , vol.66 , pp. 3992
- Lievre¹

45
- 70349510460
- 10.1158/1541-7786.MCR-08-0522 19737969 1:CAS:528:DC%2BD1MXhtFCjtbvN
- Lin 2009 Mol Cancer Res 7 1466 10.1158/1541-7786.MCR-08-0522 19737969 1:CAS:528:DC%2BD1MXhtFCjtbvN
- (2009) Mol Cancer Res , vol.7 , pp. 1466
- Lin¹

46
- 2342471392
- Activating mutations in the epidermal growth factor receptor nderlying responsiveness of Non-Small-Cell Lung Cancer to Gefitinib
- DOI 10.1056/NEJMoa040938
- Lynch 2004 N Engl J Med 350 2129 10.1056/NEJMoa040938 15118073 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
- (2004) New England Journal of Medicine , vol.350 , Issue.21 , pp. 2129-2139
- Lynch, T.J.¹ Bell, D.W.² Sordella, R.³ Gurubhagavatula, S.⁴ Okimoto, R.A.⁵ Brannigan, B.W.⁶ Harris, P.L.⁷ Haserlat, S.M.⁸ Supko, J.G.⁹ Haluska, F.G.¹⁰ Louis, D.N.¹¹ Christiani, D.C.¹² Settleman, J.¹³ Haber, D.A.¹⁴

47
- 47949114668
- 10.1056/NEJMoa0800668 18596266 1:CAS:528:DC%2BD1cXovFSqtbc%3D
- Maheswaran 2008 N Engl J Med 359 366 10.1056/NEJMoa0800668 18596266 1:CAS:528:DC%2BD1cXovFSqtbc%3D
- (2008) N Engl J Med , vol.359 , pp. 366
- Maheswaran¹

48
- 0023904523
- 2834047 1:CAS:528:DyaL1cXktFyjt78%3D
- Malden 1988 Cancer Res 48 2711 2834047 1:CAS:528:DyaL1cXktFyjt78%3D
- (1988) Cancer Res , vol.48 , pp. 2711
- Malden¹

49
- 70149110218
- 19794967 1:CAS:528:DC%2BD1MXhtFKrsb7I
- Marchetti 2009 Neoplasia 11 1084 19794967 1:CAS:528:DC%2BD1MXhtFKrsb7I
- (2009) Neoplasia , vol.11 , pp. 1084
- Marchetti¹

50
- 34249810645
- KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
- DOI 10.1158/1078-0432.CCR-06-3043
- Massarelli 2007 Clin Cancer Res 13 2890 10.1158/1078-0432.CCR-06-3043 17504988 1:CAS:528:DC%2BD2sXlt1Krs7g%3D (Pubitemid 46849563)
- (2007) Clinical Cancer Research , vol.13 , Issue.10 , pp. 2890-2896
- Massarelli, E.¹ Varella-Garcia, M.² Tang, X.³ Xavier, A.C.⁴ Ozburn, N.C.⁵ Liu, D.D.⁶ Bekele, B.N.⁷ Herbst, R.S.⁸ Wistuba, I.I.⁹

51
- 0021363327
- 6318979 1:CAS:528:DyaL2cXhtF2ju7k%3D
- Masui 1984 Cancer Res 44 1002 6318979 1:CAS:528:DyaL2cXhtF2ju7k%3D
- (1984) Cancer Res , vol.44 , pp. 1002
- Masui¹

52
- 0041629450
- Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
- DOI 10.1200/JCO.2003.01.504
- Mendelsohn 2003 J Clin Oncol 21 2787 10.1200/JCO.2003.01.504 12860957 1:CAS:528:DC%2BD2cXptlCktbo%3D (Pubitemid 46606324)
- (2003) Journal of Clinical Oncology , vol.21 , Issue.14 , pp. 2787-2799
- Mendelsohn, J.¹ Baselga, J.²

53
- 69949162760
- 10.1056/NEJMoa0810699 19692680 1:CAS:528:DC%2BD1MXhtVygsbfK
- Mok 2009 N Engl J Med 361 947 10.1056/NEJMoa0810699 19692680 1:CAS:528:DC%2BD1MXhtVygsbfK
- (2009) N Engl J Med , vol.361 , pp. 947
- Mok¹

54
- 17844362179
- Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study
- DOI 10.1016/S1470-2045(05)70102-9, PII S1470204505701029
- Moroni 2005 Lancet Oncol 6 279 10.1016/S1470-2045(05)70102-9 15863375 1:CAS:528:DC%2BD2MXjs1Krsb8%3D (Pubitemid 40590264)
- (2005) Lancet Oncology , vol.6 , Issue.5 , pp. 279-286
- Moroni, M.¹ Veronese, S.² Benvenuti, S.³ Marrapese, G.⁴ Sartore-Bianchi, A.⁵ Di Nicolantonio, F.⁶ Gambacorta, M.⁷ Siena, S.⁸ Bardelli, A.⁹

55
- 41049090971
- Results of a randomized phase III study to compare the overall survival of gefitinib versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens
- Niho SIY, Tamura T et al (2007) Results of a randomized phase III study to compare the overall survival of gefitinib versus docetaxel in Japanese patients with non-small cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 387s
- (2007) J Clin Oncol , vol.387 S
- Niho, S.I.Y.¹ Tamura, T.²

56
- 1642421130
- Target-based agents against ErbB receptors and their ligands: A novel approach to cancer treatment
- DOI 10.1677/erc.0.0100001
- Normanno 2003 Endocr Relat Cancer 10 1 10.1677/erc.0.0100001 12653668 1:CAS:528:DC%2BD3sXksVahtLs%3D (Pubitemid 36457237)
- (2003) Endocrine-Related Cancers , vol.10 , Issue.1 , pp. 1-21
- Normanno, N.¹ Bianco, C.² De Luca, A.³ Maiello, M.R.⁴ Salomon, D.S.⁵

57
- 2342624080
- EGFR mutations in lung, cancer: Correlation with clinical response to gefitinib therapy
- DOI 10.1126/science.1099314
- Paez 2004 Science 304 1497 10.1126/science.1099314 15118125 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
- (2004) Science , vol.304 , Issue.5676 , pp. 1497-1500
- Paez, J.G.¹ Janne, P.A.² Lee, J.C.³ Tracy, S.⁴ Greulich, H.⁵ Gabriel, S.⁶ Herman, P.⁷ Kaye, F.J.⁸ Lindeman, N.⁹ Boggon, T.J.¹⁰ Naoki, K.¹¹ Sasaki, H.¹² Fujii, Y.¹³ Eck, M.J.¹⁴ Sellers, W.R.¹⁵ Johnson, B.E.¹⁶ Meyerson, M.¹⁷

58
- 4444344330
- EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib
- DOI 10.1073/pnas.0405220101
- Pao 2004 Proc Natl Acad Sci U S A 101 13306 10.1073/pnas.0405220101 15329413 1:CAS:528:DC%2BD2cXnvFems70%3D (Pubitemid 39209661)
- (2004) Proceedings of the National Academy of Sciences of the United States of America , vol.101 , Issue.36 , pp. 13306-13311
- Pao, W.¹ Miller, V.² Zakowski, M.³ Doherty, J.⁴ Politi, K.⁵ Sarkaria, I.⁶ Singh, B.⁷ Heelan, R.⁸ Rusch, V.⁹ Fulton, L.¹⁰ Mardis, E.¹¹ Kupfer, D.¹² Wilson, R.¹³ Kris, M.¹⁴ Varmus, H.¹⁵

59
- 18244371651
- Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
- DOI 10.1371/journal.pmed.0020073, e73
- Pao 2005 PLoS Med 2 e73 10.1371/journal.pmed.0020073 15737014 1:CAS:528:DC%2BD2MXjtFyhsLo%3D (Pubitemid 40629469)
- (2005) PLoS Medicine , vol.2 , Issue.3 , pp. 0225-0235
- Pao, W.¹ Miller, V.A.² Politi, K.A.³ Riely, G.J.⁴ Somwar, R.⁵ Zakowski, M.F.⁶ Kris, M.G.⁷ Varmus, H.⁸

60
- 15744372810
- KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
- DOI 10.1371/journal.pmed.0020017, e17
- Pao 2005 PLoS Med 2 e17 10.1371/journal.pmed.0020017 15696205 1:CAS:528:DC%2BD2MXit1ygtL4%3D (Pubitemid 40412734)
- (2005) PLoS Medicine , vol.2 , Issue.1 , pp. 0057-0061
- Pao, W.¹ Wang, T.Y.² Riely, G.J.³ Miller, V.A.⁴ Pan, Q.⁵ Ladanyi, M.⁶ Zakowski, M.F.⁷ Heelan, R.T.⁸ Kris, M.G.⁹ Varmus, H.E.¹⁰

61
- 4344646459
- Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
- DOI 10.1200/JCO.2004.11.057
- Perez-Soler 2004 J Clin Oncol 22 3238 10.1200/JCO.2004.11.057 15310767 1:CAS:528:DC%2BD2cXpsVGrsLg%3D (Pubitemid 41103678)
- (2004) Journal of Clinical Oncology , vol.22 , Issue.16 , pp. 3238-3247
- Perez-Soler, R.¹ Chachoua, A.² Hammond, L.A.³ Rowinsky, E.K.⁴ Huberman, M.⁵ Karp, D.⁶ Rigas, J.⁷ Clark, G.M.⁸ Santabarbara, P.⁹ Bonomi, P.¹⁰

62
- 0343819997
- 10.1159/000030116 10686540 1:CAS:528:DC%2BD3cXit12lsL0%3D
- Porebska 2000 Tumour Biol 21 105 10.1159/000030116 10686540 1:CAS:528:DC%2BD3cXit12lsL0%3D
- (2000) Tumour Biol , vol.21 , pp. 105
- Porebska¹

63
- 32944481596
- Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
- DOI 10.1158/1078-0432.CCR-05-1846
- Riely 2006 Clin Cancer Res 12 839 10.1158/1078-0432.CCR-05-1846 16467097 1:CAS:528:DC%2BD28XhtFeiurk%3D (Pubitemid 43259866)
- (2006) Clinical Cancer Research , vol.12 , Issue.3 , pp. 839-844
- Riely, G.J.¹ Pao, W.² Pham, D.³ Li, A.R.⁴ Rizvi, N.⁵ Venkatraman, E.S.⁶ Zakowski, M.F.⁷ Kris, M.G.⁸ Ladanyi, M.⁹ Miller, V.A.¹⁰

64
- 0023707058
- 3048648 1:STN:280:DyaL1M%2Fgt1Ohtg%3D%3D
- Rodenhuis 1988 Cancer Res 48 5738 3048648 1:STN:280: DyaL1M%2Fgt1Ohtg%3D%3D
- (1988) Cancer Res , vol.48 , pp. 5738
- Rodenhuis¹

65
- 69949186250
- 10.1056/NEJMoa0904554 19692684 1:CAS:528:DC%2BD1MXhtVOqsL7M
- Rosell 2009 N Engl J Med 361 958 10.1056/NEJMoa0904554 19692684 1:CAS:528:DC%2BD1MXhtVOqsL7M
- (2009) N Engl J Med , vol.361 , pp. 958
- Rosell¹

66
- 0028955388
- 10.1016/1040-8428(94)00144-I 7612182 1:STN:280:DyaK2Mzjs1KgsQ%3D%3D
- Salomon 1995 Crit Rev Oncol Hematol 19 183 10.1016/1040-8428(94)00144-I 7612182 1:STN:280:DyaK2Mzjs1KgsQ%3D%3D
- (1995) Crit Rev Oncol Hematol , vol.19 , pp. 183
- Salomon¹

67
- 0002823211
- Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
- Saltz L RM, Hochster H et al (2001) Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 20
- (2001) Proc Am Soc Clin Oncol , vol.20
- Saltz, L.R.M.¹ Hochster, H.²

68
- 33847323129
- Epidermal growth factor receptor mutations in lung cancer
- DOI 10.1038/nrc2088, PII NRC2088
- Sharma 2007 Nat Rev Cancer 7 169 10.1038/nrc2088 17318210 1:CAS:528:DC%2BD2sXitVGrsbo%3D (Pubitemid 46316032)
- (2007) Nature Reviews Cancer , vol.7 , Issue.3 , pp. 169-181
- Sharma, S.V.¹ Bell, D.W.² Settleman, J.³ Haber, D.A.⁴

69
- 70349336416
- 10.1200/JCO.2009.22.6993 19667264 1:CAS:528:DC%2BD1MXht1WisbvF
- Shaw 2009 J Clin Oncol 27 4247 10.1200/JCO.2009.22.6993 19667264 1:CAS:528:DC%2BD1MXht1WisbvF
- (2009) J Clin Oncol , vol.27 , pp. 4247
- Shaw¹

70
- 22044445517
- Erlotinib in previously treated non-small-cell lung cancer
- DOI 10.1056/NEJMoa050753
- Shepherd 2005 N Engl J Med 353 123 10.1056/NEJMoa050753 16014882 1:CAS:528:DC%2BD2MXmtFaksbo%3D (Pubitemid 41058344)
- (2005) New England Journal of Medicine , vol.353 , Issue.2 , pp. 123-132
- Shepherd, F.A.¹ Pereira, J.R.² Ciuleanu, T.³ Eng, H.T.⁴ Hirsh, V.⁵ Thongprasert, S.⁶ Campos, D.⁷ Maoleekoonpiroj, S.⁸ Smylie, M.⁹ Martins, R.¹⁰ Van Kooten, M.¹¹ Dediu, M.¹² Findlay, B.¹³ Tu, D.¹⁴ Johnston, D.¹⁵ Bezjak, A.¹⁶ Clark, G.¹⁷ Santabarbara, P.¹⁸ Seymour, L.¹⁹

71
- 0023192376
- 3476783 1:CAS:528:DyaL2sXmtFGmtb0%3D
- Sobol 1987 J Natl Cancer Inst 79 403 3476783 1:CAS:528:DyaL2sXmtFGmtb0%3D
- (1987) J Natl Cancer Inst , vol.79 , pp. 403
- Sobol¹

72
- 65949086609
- 10.1158/0008-5472.CAN-08-4055 19351834 1:CAS:528:DC%2BD1MXksV2hs7g%3D
- Sos 2009 Cancer Res 69 3256 10.1158/0008-5472.CAN-08-4055 19351834 1:CAS:528:DC%2BD1MXksV2hs7g%3D
- (2009) Cancer Res , vol.69 , pp. 3256
- Sos¹

73
- 0022551229
- 3002608 1:CAS:528:DyaL28XhsVKgtro%3D
- Stoscheck 1986 Cancer Res 46 1030 3002608 1:CAS:528:DyaL28XhsVKgtro%3D
- (1986) Cancer Res , vol.46 , pp. 1030
- Stoscheck¹

74
- 0034079777
- 10764044 1:CAS:528:DC%2BD3cXivVyhurs%3D
- Sung 2000 Brain Pathol 10 249 10764044 1:CAS:528:DC%2BD3cXivVyhurs%3D
- (2000) Brain Pathol , vol.10 , pp. 249
- Sung¹

75
- 27544503230
- Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
- DOI 10.1016/S0140-6736(05)67625-8, PII S0140673605676258
- Thatcher 2005 Lancet 366 1527 10.1016/S0140-6736(05)67625-8 16257339 1:CAS:528:DC%2BD2MXhtFKhsbfP (Pubitemid 41540110)
- (2005) Lancet , vol.366 , Issue.9496 , pp. 1527-1537
- Thatcher, N.¹ Chang, A.² Parikh, P.³ Pereira, J.R.⁴ Ciuleanu, T.⁵ Von Pawel, J.⁶ Thongprasert, S.⁷ Tan, E.H.⁸ Pemberton, K.⁹ Archer, V.¹⁰ Carroll, K.¹¹

76
- 34249821410
- An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer
- Tsao MZC, Sakurada A et al (2006) An analysis of the prognostic and predictive importance of K-ras mutation status in the National Cancer Institute of Canada Clinical Trials Group BR.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer. J Clin Oncol 365s
- (2006) J Clin Oncol , vol.365 S
- Tsao, M.Z.C.¹ Sakurada, A.²

77
- 0033063774
- The epidermal growth factor receptor and its inhibition in cancer therapy
- DOI 10.1016/S0163-7258(98)00045-X, PII S016372589800045X
- Woodburn 1999 Pharmacol Ther 82 241 10.1016/S0163-7258(98)00045-X 10454201 1:CAS:528:DyaK1MXjvFOhtLw%3D (Pubitemid 29255919)
- (1999) Pharmacology and Therapeutics , vol.82 , Issue.2-3 , pp. 241-250
- Woodburn, J.R.¹

78
- 52049099853
- 10.1158/0008-5472.CAN-07-5084 18757405 1:CAS:528:DC%2BD1cXhtVCrs7%2FK
- Yamamoto 2008 Cancer Res 68 6913 10.1158/0008-5472.CAN-07-5084 18757405 1:CAS:528:DC%2BD1cXhtVCrs7%2FK
- (2008) Cancer Res , vol.68 , pp. 6913
- Yamamoto¹

79
- 0023912033
- 3380099 1:CAS:528:DyaL1cXhvF2hurs%3D
- Yamazaki 1988 Mol Cell Biol 8 1816 3380099 1:CAS:528:DyaL1cXhvF2hurs%3D
- (1988) Mol Cell Biol , vol.8 , pp. 1816
- Yamazaki¹

80
- 45749120442
- 10.1200/JCO.2007.15.6695 18509184 1:CAS:528:DC%2BD1cXnvVOhtr8%3D
- Yang 2008 J Clin Oncol 26 2745 10.1200/JCO.2007.15.6695 18509184 1:CAS:528:DC%2BD1cXnvVOhtr8%3D
- (2008) J Clin Oncol , vol.26 , pp. 2745
- Yang¹

81
- 52149114884
- 10.1097/PAS.0b013e31816597ca 18636014
- Yousem 2008 Am J Surg Pathol 32 1317 10.1097/PAS.0b013e31816597ca 18636014
- (2008) Am J Surg Pathol , vol.32 , pp. 1317
- Yousem¹

82
- 33847406095
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity
- DOI 10.1016/j.ccr.2006.12.017, PII S1535610807000281
- Yun 2007 Cancer Cell 11 217 10.1016/j.ccr.2006.12.017 17349580 1:CAS:528:DC%2BD2sXjsVymtL4%3D (Pubitemid 46349842)
- (2007) Cancer Cell , vol.11 , Issue.3 , pp. 217-227
- Yun, C.-H.¹ Boggon, T.J.² Li, Y.³ Woo, M.S.⁴ Greulich, H.⁵ Meyerson, M.⁶ Eck, M.J.⁷

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.